PHARMACEUTICAL COMPOSITION COMPRISING THE ETHYLACETATE FRACTION OF OKMISOO EXTRACT AS AN EFFECTIVE COMPONENT FOR PREVENTION OR TREATMENT OF THROMBOSIS AND HEALTH FUNCTIONAL FOOD COMPRISING THE SAME
The present invention relates to an antithrombotic composition containing an ethyl acetate fraction of an extract of Silk of Zea mays Linne as an active ingredient, and more specifically, to an ethyl acetate fraction of a hydrothermal extract of Okmi water as an active ingredient. The present invention relates to a pharmaceutical composition for the prevention or treatment / improvement of thrombosis through blood coagulation inhibition and a dietary supplement. Ethyl acetate fraction of oxime water extract as an active ingredient of the pharmaceutical composition for the prevention or treatment of thrombosis of the present invention and health functional food, as demonstrated through the examples herein, clotting production-related enzyme inhibition and blood coagulation factor It exhibits strong antithrombotic activity by the inhibition of, and shows no hemolytic activity against human erythrocytes, excellent thermal stability, and loss of the inhibitory effect of blood clotting production enzymes and coagulation factor in acidic conditions and plasma of pH 2 Since it does not appear, it is expected to be used for the prevention and treatment of thrombosis such as ischemic stroke and hemorrhagic stroke by improving blood circulation, and the active ingredient is processed in various forms such as extract, powder, pills, tablets and is always taken. The pharmaceutical industry has a great effect in the possible form Commodity industries will be very useful inventions.본 발명은 옥미수(Silk of Zea mays Linne) 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 항혈전 조성물에 관한 것으로서, 보다 상세하게는, 옥미수의 열수 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 혈액 응고 저해를 통한 혈전증의 예방 또는 치료/개선용 약학적 조성물 및 건강 기능 식품에 관한 것이다. 본 발명의 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품의 유효성분으로서의 옥미수 추출물의 에틸아세테이트 분획물은, 본 명세서의 실시예를 통해 증명된 바와 같이, 혈전 생성 관련 효소 저해 및 혈액 응고 인자의 저해에 의한 강력한 항혈전 활성을 나타냄과 동시에, 인간 적혈구에 대한 용혈 활성을 전혀 나타내지 않고, 열 안정성이 우수하고, pH 2의 산성 조건 및 혈장 내에서도 혈전 생성 관련 효소 및 혈액 응고 인자 저해 효과의 손실이 나타나지 않으므로, 혈행 개선을 통해 허혈성 뇌졸중 및 출혈성 뇌졸중과 같은 혈전증의 예방 및 치료용으로 사용할 수
